Neuromyelitis Optica Spectrum Disorder: Updates on Diagnosis and Treatment Management

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that is characterized by inflammation in the optic nerve and spinal cord. Unfortunately, early stages of NMOSD are frequently misdiagnosed as multiple sclerosis or other diseases. Diagnosis is typically based on the presence of key clinical characteristics"aquaporin-4 (AQP4) antibody status and magnetic resonance imaging. The application of newer diagnostic criteria may assist in an earlier and more accurate diagnosis of NMOSD in those who may have been diagnosed with other diseases.

Until recently, the treatment options for NMOSD have been limited. Therefore, it is important for healthcare providers to examine current NMOSD treatments for their mechanisms of action and modes of administration and to evaluate the clinical evidence regarding their safety and efficacy.

In this continuing education presentation, experts in the field present didactic information, review cases of NMOSD, and engage in a panel discussion to summarize evidence-based diagnostic criteria and best practices that aid in the differential diagnosis of NMOSD. This program will aid clinicians in therapeutic decision-making regarding the use of current NMOSD agents based on their mechanisms of action, efficacy, safety, and mode of administration. Finally, faculty examines the interprofessional approaches to diagnose and manage patients with NMOSD.